<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108615</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-013-0S3</org_study_id>
    <nct_id>NCT00108615</nct_id>
  </id_info>
  <brief_title>Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance</brief_title>
  <official_title>Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or
      metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose
      tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle
      biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of
      impaired glucose tolerance is ameliorated by pioglitazone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The progression to type 2 diabetes represents an evolution, which results from a vicious
      cycle where both glucotoxicity and lipotoxicity act to reduce insulin secretion and insulin
      action. Lipotoxicity is a new concept, which refers to overaccumulation of lipids in
      non-adipose tissue reflecting increased free fatty acid delivery. Increased fat content of
      skeletal muscle and islet cell is associated with insulin resistance and impaired pancreatic
      -cell function respectively in animal models. Whether lipotoxicity is the link between
      obesity and diabetes, in humans, and whether reducing intracellular fat content will improve
      insulin secretion and sensitivity in humans is not known. In this study, we will focus on
      obese subjects with impaired glucose tolerance (IGT) who have not yet developed glucose
      toxicity. We will examine insulin secretion, insulin action, hepatic glucose production, and
      muscle lipid metabolism in response to two insulin sensitizers with two different modes of
      action. We propose that thiazolidinediones will improve cell function by reversing
      lipotoxicity as reflective in reduced muscle lipid accumulation.

      Hypothesis 1. In subjects with impaired glucose tolerance, who are insulin resistant and also
      have an insulin secretory defect, thiazolidinediones, but not biguanides, improve cell
      function.

      Hypothesis 2. In subjects with impaired glucose tolerance, thiazolidinediones, but not
      biguanides, decrease the accumulation of fat in non-adipose tissues including muscle,
      pancreas, liver and myocardium.

      Specific Aim 1. Fifty subjects with impaired glucose tolerance will be recruited and
      randomized to pioglitazone or metformin treatment

      Specific Aim 2. cell function will be evaluated by measuring changes in acute insulin
      response to glucose and non-glucose secretagogues in subjects with IGT and it will be
      compared in response to treatment with pioglitazone versus metformin.

      Specific Aim 3. The muscle fat content will be evaluated as the surrogate measure for
      lipotoxicity and overaccumulation of fat in non-adipose tissue. From the muscle biopsy
      specimens, we will measure the amount of intramyocellular triglyceride before and after
      treatment with pioglitazone versus metformin.

      Specific Aim 4. Adipose tissue cytokine expression is associated with changes in muscle lipid
      accumulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of pioglitazone and metformin on ectopic lipid accumulation</measure>
    <time_frame>4 yr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of pioglitazone and metformin on beta cell responsiveness</measure>
    <time_frame>4 yr</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CT scans</intervention_name>
    <description>To measure changes in adipose tissue volumes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>To detect a change in glucose tolerance</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance

          -  Body mass index (BMI) of 28-38

        Exclusion Criteria:

          -  Heart disease

          -  Renal disease

          -  Liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip A Kern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Arkansas Veterans HCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Arkansas Veterans HCS</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005 May;288(5):E930-4. Epub 2005 Jan 4.</citation>
    <PMID>15632102</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Gregorio GB, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles LM, Ranganathan G, Peterson CA, McGehee RE, Kern PA. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes. 2005 Aug;54(8):2305-13.</citation>
    <PMID>16046295</PMID>
  </results_reference>
  <results_reference>
    <citation>Bodles AM, Varma V, Yao-Borengasser A, Phanavanh B, Peterson CA, McGehee RE Jr, Rasouli N, Wabitsch M, Kern PA. Pioglitazone induces apoptosis of macrophages in human adipose tissue. J Lipid Res. 2006 Sep;47(9):2080-8. Epub 2006 Jun 23.</citation>
    <PMID>16799131</PMID>
  </results_reference>
  <results_reference>
    <citation>Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T. Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. J Biol Chem. 2004 Nov 12;279(46):47626-32. Epub 2004 Aug 31.</citation>
    <PMID>15339912</PMID>
  </results_reference>
  <results_reference>
    <citation>Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab. 2006 Jan;290(1):E42-E46. Epub 2005 Aug 23.</citation>
    <PMID>16118250</PMID>
  </results_reference>
  <results_reference>
    <citation>Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1100-5. Epub 2006 Jun 27.</citation>
    <PMID>16803857</PMID>
  </results_reference>
  <results_reference>
    <citation>Ranganathan G, Unal R, Pokrovskaya I, Yao-Borengasser A, Phanavanh B, Lecka-Czernik B, Rasouli N, Kern PA. The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J Lipid Res. 2006 Nov;47(11):2444-50. Epub 2006 Aug 7.</citation>
    <PMID>16894240</PMID>
  </results_reference>
  <results_reference>
    <citation>Rasouli N, Kern PA, Reece EA, Elbein SC. Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E359-65. Epub 2006 Sep 12.</citation>
    <PMID>16968813</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao-Borengasser A, Rasouli N, Varma V, Miles LM, Phanavanh B, Starks TN, Phan J, Spencer HJ 3rd, McGehee RE Jr, Reue K, Kern PA. Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor gamma activation. Diabetes. 2006 Oct;55(10):2811-8.</citation>
    <PMID>17003347</PMID>
  </results_reference>
  <results_reference>
    <citation>Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ 3rd, McGehee RE Jr, Fried SK, Kern PA. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab. 2007 Feb;92(2):666-72. Epub 2006 Nov 7.</citation>
    <PMID>17090638</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Croce MA, Gropler MC, Varma V, Yao-Borengasser A, Rasouli N, Kern PA, Finck BN, Bickel PE. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes. 2006 Dec;55(12):3418-28.</citation>
    <PMID>17130488</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ 3rd, Rashidi AA, McGehee RE Jr, Fried SK, Kern PA. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab. 2007 Jul;92(7):2590-7. Epub 2007 Jun 26.</citation>
    <PMID>17595259</PMID>
  </results_reference>
  <results_reference>
    <citation>Varma V, Yao-Borengasser A, Bodles AM, Rasouli N, Phanavanh B, Nolen GT, Kern EM, Nagarajan R, Spencer HJ 3rd, Lee MJ, Fried SK, McGehee RE Jr, Peterson CA, Kern PA. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes. 2008 Feb;57(2):432-9. Epub 2007 Dec 5.</citation>
    <PMID>18057090</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2005</study_first_submitted>
  <study_first_submitted_qc>April 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2005</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kern, Philip - Principal Investigator</name_title>
    <organization>Department of Veterans Affairs</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

